RxDoctor Payments Data

Pujan Patel, MD

Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1518351873

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $44,669 of the $66,497 with a category attached, or 67.2%. Cvrx, Inc. accounts for 85.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $36,357 and has fallen 90.9% since, to $3,296 in 2025.

$66,497in general payments, 2019–2025

Across 199 payments — averaging $334.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$57K
  • Abbott$6K
  • Abiomed$1K
  • Bayer$921
  • Pfizer$423
  • Daxor Corporation$414
  • plus $945 from 15 others

What the payments were for

  • Consulting fees$44,66967%
  • Travel & lodging$10,43016%
  • Food & beverage$11,39917%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,497 in reported general payments places this provider in the 70th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

See all advanced heart failure and transplant cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$96,692
Medicare patients
259
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$43,358
EntrestoSacubitril/Valsartan12$10,157
FarxigaDapagliflozin Propanediol11$9,203
Tacrolimus70$8,931
Mycophenolic AcidMycophenolate Sodium21$2,986
Mycophenolate Mofetil35$2,738
Bumetanide21$1,109
Pantoprazole Sodium75$885
Eplerenone11$707
Warfarin Sodium57$631
Rosuvastatin Calcium46$486
Carvedilol61$469
Nifedipine ErNifedipine16$456
Losartan Potassium42$438
Hydralazine Hcl28$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$10,15712 claims
AstraZenecaFarxiga$18$9,20311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

Other advanced heart failure and transplant cardiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →